British man captured while fighting with Ukraine    Far-right candidate takes shock lead in Romania presidential election    Indians risk it all to chase the American Dream    Ireland hardens illegal immigration response    Al Ittihad claims top spot in Saudi Pro League after victory over Al Fateh    Do cigarettes belong in a museum?    Saudi Arabia joins international partnership initiative to boost hydrogen economy    Riyadh Emir inaugurates International Conference on Conjoined Twins in Riyadh    Saudi delegation participates in the 7th U20 Deans Summit in Brazil    Al-Jubeir discusses with EU officials enhancing bilateral cooperation    GASTAT: Non-oil exports up 22.8% in September 2024    Saudi Arabia to host 28th Annual World Investment Conference in Riyadh    Saudi Arabia allows licensed flour milling companies to export flour    Al Khaleej stuns Al Hilal with 3-2 victory, ending 57-match unbeaten run    SFDA move to impose travel ban on workers of food outlets in the event of food poisoning    Al Okhdood halts Al Shabab's winning streak with a 1-1 draw in Saudi Pro League    Saudi musical marvels takes center stage in Tokyo's iconic opera hall    Al Khaleej qualifies for Asian Men's Club League Handball Championship final    Katy Perry v Katie Perry: Singer wins right to use name in Australia    Sitting too much linked to heart disease –– even if you work out    Order vs. Morality: Lessons from New York's 1977 Blackout    India puts blockbuster Pakistani film on hold    The Vikings and the Islamic world    Filipino pilgrim's incredible evolution from an enemy of Islam to its staunch advocate    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Don't rule out AIDS vaccine just yet
By Seth Berkley
Published in The Saudi Gazette on 20 - 10 - 2009

VACCINE researchers don't often find themselves at the center of public controversies. But a storm has erupted over the announcement last month that an experimental AIDS vaccine tested in Thailand proved modestly effective. It was billed as a major scientific advance – the long-awaited hard evidence that it is possible to inoculate people against AIDS. But now the trial has been called into question in a way that is overblown and possibly destructive.
At a biotech conference last week, I asked a major industry scientist what he thought of the Thai trial announcement, and, although no additional data had been presented, he replied simply, “I don't believe it.” Unfortunately, such pessimism may be hard to dispel and may ultimately thwart other efforts to develop an AIDS vaccine.
Even before this controversy erupted, it had been an effort to maintain sufficient support for AIDS vaccine research and development. In 2008, private and public spending on this vital mission declined by 10 percent from the year before. A few fanatical AIDS activists have even called for ending the American government's considerable support for AIDS vaccine research, and spending the money instead on AIDS treatment. Patient care is vital, of course, but it alone can only mitigate, not end, the pandemic.
This is why it is essential to clear things up.
The Thai study was the largest AIDS vaccine trial yet, following 16,402 volunteers for six years. It was a collaborative effort by, among others, the United States military, the National Institutes of Health and the Thai Health Ministry. (The organization I head, a nonprofit that conducts vaccine research and development but was not involved and has no commercial interest in the candidates tested.) The trial partners initially announced that the vaccine combination reduced the risk of infection by 31.2 percent in a statistically significant analysis.
A few days later, the trial collaborators began to brief researchers privately about additional data, including a second type of analysis that indicated the vaccine regimen had been slightly less effective than the first analysis suggested. This second analysis was not statistically significant, meaning that chance, rather than the protective effect of the vaccine candidate, might explain why fewer volunteers in the vaccinated group than in the placebo group were infected with HIV.
Some researchers questioned why both analyses weren't announced at the same time – which certainly would have been preferable – and suggested to reporters that the second analysis called the first one into doubt. The trial sponsors say they thought the complexities of the second analysis and all additional data were best explored in a peer-reviewed paper in a scientific journal and at a presentation at the AIDS Vaccine Conference in Paris this week. But with news outlets reporting that the trial results may be a fluke, there is a risk that they will be forever tainted, whatever the final analyses show. What's more, the stain of dubiousness may remain on all AIDS vaccine research and development.
That would be a shame. Although the candidate duo tested in the Thai trial did not prove to be a vaccine ready for the market, it may provide an unprecedented opportunity to learn how an AIDS vaccine can work. A comparison of blood samples from volunteers could indicate what specific immune responses the combination may have activated to provide protection. If so, this knowledge could help scientists improve upon the more promising candidates that have emerged since the trial candidates were designed a decade ago, and determine which ones are most likely to work.
This illustrates why the controversy over statistical significance is exaggerated. Whether you consider the first or second analysis, the observed effect of the Thai candidates was either just above or below the level of statistical significance. Statisticians will tell you it is possible to observe an effect and have reason to think it's real even if it's not statistically significant. And if you think it's real, you ought to examine it carefully.
Even if the Thai vaccine regimen turns out, on examination, to have had no real benefit, researchers will still learn from the trial, as they do from every study. Moreover, other noteworthy advances featured at the Paris conference this week will offer fresh hope for an AIDS vaccine. Years of investment and dogged science are providing leads for solving one of today's most pressing research challenges. Some 7,400 new HIV infections occur daily throughout the world. Clearly we need better methods of preventing the spread of HIV, and no public health intervention is more powerful or cost-effective against infectious disease than a vaccine. – New York Times
Seth Berkley is the president and chief executive of the International AIDS Vaccine Initiative. __


Clic here to read the story from its source.